Navigation Links
Sinovac to Participate in Four Investor Conferences in September 2011
Date:8/30/2011

BEIJING, Aug. 30, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that Dr. Weidong Yin, President and CEO, Ms. Nan Wang, Interim Chief Financial Officer, and Ms. Helen Yang, Investor Relations Manager, are scheduled to attend four upcoming investor conferences in New York City and Boston.

  • Rodman & Renshaw Annual Global Investment Conference, New York City
  • Sinovac is scheduled to present at 2:50 pm on Monday, September 12, 2011 and will be participating in one-on-one meetings on September 12, 2011.

  • Morgan Stanley Global Healthcare Conference, New York City
  • Sinovac is scheduled to present at 1:35 pm ET on Tuesday, September 13, 2011 and will be participating in one-on-one meetings on September 13 and 14, 2011.
  • A live webcast of the presentation will be available online on the Investor Relations Home page of the Sinovac's corporate Web site at http://www.sinovac.com.

  • Morgan Stanley China Healthcare Day Conference, Boston
  • Sinovac will be participating in one-on-one meetings on Thursday, September 15, 2011

  • UBS Global Life Sciences Conference, New York City
  • Sinovac is scheduled to present at 4:00 pm ET on Monday, September 19, 2011 and will be participating in one-on-one meetings on September 19, 2011.

  • About SinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against hand, foot & mouth disease), mumps, rubella, HIB, epidemic meningitis, varicella and human rabies. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines, which is anticipated to be launched in 2011.

    Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.Helen Yang/Chris LeeSinovac Biotech Ltd.Tel: +86-10-8279-9871/9659Fax: +86-10-6296-6910Email: ir@sinovac.com Investors:Stephanie CarringtonThe Ruth GroupTel: +1-646-536-7017Email: scarrington@theruthgroup.comMedia:Victoria AguiarThe Ruth GroupTel: +1-646-536-7013Email: vaguiar@theruthgroup.com
    '/>"/>

    SOURCE Sinovac Biotech Ltd.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Sinovac to Host Conference Call to Report First Quarter 2011 Unaudited Financial Results
    2. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2010 Audited Financial Results
    3. Sinovac Participates in Two Investor Conferences in November
    4. Sinovac to Participate at 2010 Shanghai CPhI Exhibition
    5. Sinovac to Present at 2010 UBS Global Specialty Pharmaceuticals Conference
    6. Sinovac Reports Unaudited First Quarter 2010 Financial Results
    7. Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
    8. Sinovac Announces Upsizing and Pricing of Common Share Offering
    9. Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
    10. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
    11. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/23/2017)... -- GlobeImmune, Inc. today announced it has entered into a ... of its common stock to NantCell, Inc., a member ... sale of its common stock, NantCell has agreed to ... 200,000 shares, an estimated $2.0 million in value, of ... to enter into this strategic agreement with NantCell," said ...
    (Date:3/23/2017)... 23, 2017 Kineta, Inc., a biotechnology ... therapies in immuno-oncology, today announced the discovery and ... compounds that activate interferon response factor 3 (IRF3) ... immune-mediated tumor regression in a murine colon carcinoma ... demonstrated complete tumor regression to initial drug treatment ...
    (Date:3/23/2017)... GREENWOOD VILLAGE, Colo. , March 23, 2017 /PRNewswire/ ... million in Series A financing and note conversion to ... products. Cool Planet is focused on developing products that ... raised nearly $30 million in the last 18 months. ... Coppel and North Bridge Venture Partners. ...
    (Date:3/22/2017)... March 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), ... Center (RGC), U.K. Biobank and GSK to generate genetic sequence ... resource. The initiative will enable researchers to gain valuable insights ... a wide range of serious and life threatening diseases. ... Genetic evidence ...
    Breaking Biology Technology:
    (Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant kiosk ... At PTE 2017 ... Materna will present its complete end-to-end passenger journey, from ... benefit for passengers. To accelerate the whole passenger handling process, ... to take passengers through the complete integrated process with a ...
    (Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
    (Date:2/16/2017)... , Feb. 16, 2017  Genos, a community ... that it has received Laboratory Accreditation from the ... is presented to laboratories that meet stringent requirements ... scientifically rigorous processes. "Genos is committed ... laboratory practices. We,re honored to be receiving CAP ...
    Breaking Biology News(10 mins):